8-KEarnings & ResultsExhibits & Filings

BRISTOL MYERS SQUIBB CO 8-K Report, Financial Results (Jan 27, 2015)

Filed January 27, 2015For Securities:BMYCELG-RIBMYMP

Summary

Bristol-Myers Squibb Company (BMY) filed an 8-K on January 27, 2015, primarily to report its financial results for the fourth quarter and full year of 2014. The filing itself does not contain detailed financial data but rather furnishes a press release (Exhibit 99.1) and supplemental information (Exhibit 99.2) that contain the actual results. Investors should refer to these exhibits for a comprehensive understanding of the company's performance during the reported periods. The furnished press release and supplemental information likely detail key performance indicators such as revenue, earnings per share (EPS), and potentially updates on product sales, pipeline progress, and forward-looking guidance. Investors would be keenly interested in whether the company met or exceeded expectations for the quarter and the full year, and any insights provided into the company's strategic direction and outlook for 2015.

Key Highlights

  • 1BMY filed an 8-K on January 27, 2015, reporting Q4 and full-year 2014 financial results.
  • 2The 8-K filing references an attached press release (Exhibit 99.1) containing the detailed financial results.
  • 3Supplemental financial information is also furnished as Exhibit 99.2 and available on the company's website.
  • 4Investors are directed to the furnished exhibits for specific financial performance data.
  • 5The filing indicates the event date for the results announcement was January 26, 2015.

Frequently Asked Questions

The main purpose of this 8-K filing is to publicly announce and provide access to Bristol-Myers Squibb's financial results for the fourth quarter and the full twelve months of 2014. It serves as a formal disclosure mechanism for this material information.

The actual financial results are not detailed within the 8-K document itself. Instead, they are provided in Exhibit 99.1 (the press release) and Exhibit 99.2 (supplemental information), both furnished with this filing and accessible via the company's website (www.bms.com).

Investors can expect to find detailed financial metrics such as revenue, earnings per share (EPS), profit margins, and potentially commentary on key product performance, pipeline developments, and future financial guidance for the company.